Takeda Pharmaceutical Company Limited (TSE:4502) exercised an option to acquire Adaptate Biotherapeutics Ltd from Abingworth LLP on January 10, 2022. The acquisition is subject to completion of review under applicable antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the U.S. The acquisitions of Adaptate is expected to be finalised in first quarter of Takeda's fiscal year 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4,115 JPY | -0.48% | +0.61% | +1.48% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.48% | 41.84B | |
+25.61% | 660B | |
+25.87% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+7.09% | 219B | |
-9.12% | 196B | |
+5.01% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- 4502 Stock
- News Takeda Pharmaceutical Company Limited
- Takeda Pharmaceutical Company Limited exercised an option to acquire Adaptate Biotherapeutics Ltd from Abingworth LLP.